ENRIGHT PATRICK G sold $75.2M of MANE (indirect holdings)
ENRIGHT PATRICK G sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11.
Veradermics, Inc
Veradermics is a dermatologist-founded biopharmaceutical company developing treatments for prevalent aesthetic and dermatological conditions. Its lead product candidate, VDPHL01, is an extended-release oral formulation of minoxidil being studied for pattern hair loss in men and women. The company is conducting clinical trials, including three registration-directed trials, and is also evaluating VDPHL01 in an exploratory Phase 2 trial. It has no marketed products described in this profile. Veradermics aims to develop a focused portfolio of aesthetic dermatology candidates, with potential selective development in medical dermatology. It plans to commercialize VDPHL01 directly to patients through a cash-pay model if approved, supported by physician education, advertising and patient engagement. The company retains exclusive worldwide rights to its candidates and may consider strategic collaborations. Veradermics is headquartered in New Haven, Connecticut.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MANE in the last 7 days.
ENRIGHT PATRICK G sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11.
Longitude Capital Partners V, LLC sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11. Filed jointly with Longitude Venture Partners V, L.P. (10% owner).
Citigroup kept its Buy rating on Veradermics and increased its price target to $175 from $160, suggesting a 21.6% upside from the Nov 9 close of $143.95. Recent analyst price targets for the company range from $150 to $204.
Recent MANE coverage spans financial news, insider activity and earnings.
In the last 30 days, MANE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($75.2M). The most active reporter was ENRIGHT PATRICK G with 2 filings.
Large insider sell by a director suggests potential downside pressure on the stock.
Large insider sell may signal negative sentiment.
Citigroup kept its Buy rating on Veradermics and increased its price target to $175 from $160, suggesting a 21.6% upside from the Nov 9 close of $143.95. Recent analyst price targets for the company range from $150 to $204.
Positive trial data and strong cash position suggest upside potential.
Positive clinical outcomes and strong cash position suggest upside potential for MANE.
AlphAI scores every news story that mentions MANE with an AI model for sentiment and relevance, and aggregates insider trades from Veradermics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
ENRIGHT PATRICK G sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11.
Longitude Capital Partners V, LLC sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11. Filed jointly with Longitude Venture Partners V, L.P. (10% owner).
Citigroup kept its Buy rating on Veradermics and increased its price target to $175 from $160, suggesting a 21.6% upside from the Nov 9 close of $143.95. Recent analyst price targets for the company range from $150 to $204.
Veradermics reported a Q3 2026 net loss of $21.0M, up from $20.1M a year earlier, with $798.4M in cash. Positive trial data for VDPHL01 in hair loss was highlighted. R&D expenses decreased to $16.1M, while operating expenses rose to $28.8M. The company expects topline results from Study 306 in H1 2027.
Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora
Leerink Partners kept Veradermics at Outperform, raising its price target to $150 from $135, an 11.1% increase. This implies a 4.2% upside from the Nov 9 close of $143.95. Recent analyst targets range from $172 to $204.
Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.
Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, demonstrated Target Area Hair Coun
Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.
Disc Medicine (IRON) surged 38.86% to $78.93, leading healthcare gains. Cleveland-Cliffs (CLF) rose 16.34% to $14.10 in materials. Almonty Industries (ALM) fell 10.17% to $8.83, among notable decliners.